About the Report
Bridging the Gap
Reimbursement Pathways for Psychedelic Therapies addresses a critical missing piece in the development of psychedelic medicines.
In mid 2024, Floris Wolswijk and Martin Gisby met at the ICPR (Interdisciplinary Conference on Psychedelic Research) and identified a significant gap in the psychedelic medicine ecosystem. While extensive research focused on clinical efficacy and regulatory pathways, little attention was being paid to how these treatments would actually be paid for and made accessible to patients through healthcare systems.
This insight led to the development of a comprehensive report examining how psychedelic therapies can integrate into European healthcare reimbursement systems. With funding support from Norrsken Mind, a non-profit foundation dedicated to advancing psychedelic science in Europe, the project took shape over the following six months.
The report provides a clear and detailed overview of current reimbursement pathways and insurance coverage across Europe, focusing on Germany, the Netherlands, the United Kingdom, and the Czech Republic. It identifies gaps specific to psychedelic therapies and explores how existing reimbursement models can accommodate or hinder their integration.
Report Objectives
- Map the current reimbursement landscape for novel mental health treatments
- Identify barriers preventing psychedelic therapy reimbursement
- Propose viable solutions to facilitate access within existing frameworks
- Engage with key stakeholders across the healthcare ecosystem
By fostering collaboration among stakeholders and providing actionable guidance, the report aims to facilitate the integration of psychedelic therapies into standard medical practice - essential for improving access for patients living with mental health conditions that are inadequately addressed by current treatments.
The Authors
Martin Gisby of Magnetar Access brings comprehensive expertise in market access, with deep knowledge of reimbursement systems and HTA processes across Europe.
martingisby@magnetaraccess.com
LinkedIn
Floris Wolswijk, founder of Blossom, contributes extensive knowledge of psychedelic research, industry developments, and the evolving therapeutic landscape.
floris@blossomact.com
LinkedIn
Funding Partner
This report was supported by a project grant from Norrsken Mind, a non-profit foundation dedicated to advancing psychedelic science in Europe. The foundation funds high-quality research investigating the therapeutic potential of psychedelics for mental health disorders and non-profit initiatives laying the groundwork for future healthcare integration.
Collaborators
The report benefited from valuable insights and support from key collaborators including Viktor Chvátal and Sumudu Gouri Boyina from PsychedelicsEUROPE, Tadeusz Hawrot from PAREA, and Josh Hardman of Psychedelic Alpha.
"This report provides a foundation for understanding how psychedelic therapies might be integrated into European healthcare systems. Making these treatments accessible to patients will require sustained collaboration between stakeholders and creative solutions to address implementation challenges."